Lucira COVID-19 & Flu Test Packaging
EMERYVILLE, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. ("Lucira Health" or "Lucira") (Nasdaq: LHDX), a medical technology company focused on the development and commercialization of innovative infectious disease tests, announced that both its COVID-19 & Flu and COVID-19 molecular tests have received CE Mark for professional use, clearing both tests for sale and distribution throughout the European Union.
The Lucira COVID-19 & Flu and COVID-19 tests are Nucleic Acid Amplification Tests (NAAT) with sensitivity and specificity comparable to lab-based PCR assays, miniaturized to run on a palm-sized device with no separate instrument or reader, producing results in 30 minutes. Lucira's COVID-19 test is currently available in the US, Canada, Singapore, Israel, and Taiwan with millions of tests distributed to date. The Lucira COVID-19 & Flu test uses the same platform and palm-sized device design and independently tests for COVID-19, Flu A, and Flu B from a single nasal swab with results in less than 30 minutes.
"The Lucira testing platform can make highly accurate molecular point-of-care testing more accessible than previously possible with our simple test that requires no separate instrument or reader, internet connection, or power cord," said Erik Engelson, the President and CEO of Lucira Health. "Receiving CE Mark for both our COVID-19 & Flu and COVID-19 tests represents a major milestone for Lucira to expand our product-line and our geographic reach."
COVID-19 and flu have similar symptoms but distinct treatments, making tests to differentiate between these infections crucial when the viruses that cause them are both in circulation. Lucira plans to make its COVID-19 & Flu test available in the European Union beginning in the third quarter of 2022 in advance of the Northern Hemisphere influenza season.
Clinical trial results with the Lucira COVID-19 & Flu test were positive and submissions to other regulatory authorities, including the U.S. Food & Drug Administration and Health Canada, are planned for the second quarter of 2022 with decisions expected before this upcoming flu season.
About the Lucira COVID-19 Test The Lucira COVID-19 test is a Nucleic-Acid Amplification Test (NAAT). The test fits in the palm of your hand, extracts genetic material from the virus and amplifies it, similar to PCR lab tests, to detect the presence of virus earlier and more accurately than antigen tests. There is no additional equipment to purchase, such as a reader or instrument. Each Lucira test contains everything needed to run a single COVID-19 test: the test device, two AA batteries, sample vial, swab, and simple instructions.
About the Lucira COVID-19 & Flu Test The Lucira COVID-19 & Flu test is a molecular test utilizing the same platform and device design as Lucira's COVID-19 tests to provide independent diagnoses for COVID-19, Flu A, and Flu B. The single-use test fits in the palm of your hand, runs on 2 AA batteries, and with one nasal swab provides a positive or negative result for COVID-19, Flu A, and Flu B in less than 30 minutes.
About Lucira Health Lucira is a medical technology company focused on the development and commercialization of transformative and innovative infectious disease tests. Lucira's testing platform produces lab quality molecular testing in a single-use, easy-to-use, palm-size test kit powered by two AA batteries. Lucira designed its test kits to provide accurate, reliable, and on-the-spot molecular test results anywhere and at any time.
For more information, visit www.lucirahealth.com.
Forward Looking Statements Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "can," "plans," "may," "anticipates," "expects," and similar expressions are intended to identify forward-looking statements. Forward-looking statements include statements regarding, among others, Lucira's planned regulatory submissions of its COVID-19 and Flu test to other regulatory authorities and the timing and availability of Lucira's COVID-19 & Flu test available throughout the European Union. These forward-looking statements are based upon Lucira's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including Lucira's ability to increase production, streamline operations and increase product availability; the success of Lucira's test platform with COVID-19 including its variants, Flu A and Flu B; the extent and duration of the COVID-19 pandemic and Lucira's expectations regarding customer and user demand for its COVID-19 test and the COVID-19 and Flu test; Lucira's ability to obtain and maintain regulatory approval for its tests, including Lucira's existing Emergency Use Authorization for its COVID-19 test and LUCI Pass; Lucira's expectations around the timing of submission and receipt of regulatory approval for its tests; the performance of, and Lucira's reliance on, third parties in connection with the commercialization of its tests, including Jabil Inc., Switch Health and Lucira's single-source suppliers; Lucira's ability to successfully continue to expand internationally; any impact on Lucira's ability to market its tests; demand for Lucira's tests due to deferral of procedures using its tests or disruption in its supply chain; Lucira's ability to achieve or sustain profitability; Lucira's ability to gain market acceptance for its tests and to accurately forecast and meet customer demand; Lucira's ability to compete successfully; Lucira's ability to enhance and expand its product offerings; Lucira's ability to accurately predict continued expansion; Lucira's ability to accurately forecast revenue; development and manufacturing problems; capacity constraints or delays in production of Lucira's tests; maintenance of coverage and adequate reimbursement for procedures using Lucira's tests; and test defects or failures. These and other risks and uncertainties are described more fully in the "Risk Factors" section and elsewhere in Lucira's filings with the Securities and Exchange Commission and available at www.sec.gov, including in its most recent Annual Report on Form 10-K and subsequently filed reports. Any forward-looking statements that Lucira makes in this announcement speak only as of the date of this press release, and Lucira assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise after the date of this press release, except as required under applicable law.
Media Contact Mike Stommel Lucira@luckybreakpr.com 323-333-2901
Investor Contact Greg Chodaczek Investorrelations@lucirahealth.com 332-895-3230
Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/67d6232b-f241-4877-94c9-597fab2940f3
https://www.globenewswire.com/NewsRoom/AttachmentNg/5e558804-7e23-41fb-bff9-58b687197310
The U.S. Food and Drug Administration approved Eli Lilly novel treatment for diabetes on Friday, in a widely anticipated move after the drug led to impressive drops in blood sugar and body weight in clinical trials. Lilly stock (ticker: LLY) closed up just 0.3% Friday, at $291.63, but it has proved a favorite even in a faltering market. While the has dropped 4.4% in the past 12 months, Lilly shares are up 50%.
Bodybuilder Charles Atlas sought to turn Americans from 'Chump to Champ.' Lee Lockwood/Getty ImagesPromotions for “The End of Men,” Fox News host Tucker Carlson’s forthcoming documentary, lament “The total collapse of testosterone levels in American men.” Carlson’s central premise is that modern society has devitalized American men. Strength, drive and aggression are no longer in vogue, and Americans, as a result, are become weaker. This, the film implies, has ramifications for the country itsel
"I was in a medically induced coma for six weeks. There were times I was fully conscious, but I couldn't open my eyes, couldn't move a muscle, and couldn't speak. It was terrifying."View Entire Post ›
The company's current treatments dominate the cystic fibrosis market, but it's the pipeline that makes this stock so intriguing.
This new subvariant is becoming the most dominant strain of COVID-19 in the U.S., but experts say its earliest symptoms are being mistaken for common colds.
“There's plenty of blame to go around here,” says one expert.
From increased equity to the popularity of wearable medical devices, here are five predictions about the future of the American health care industry.
The Army is weighing new policies in response to the Supreme Court's expected decision to reverse Roe v. Wade and eliminate protections on abortion rights across the country, the service's senior enlisted leader told Congress.
Despite the popularity of vegan and vegetarian diets, a majority of people in the U.S. still do eat meat. In fact, according to a 2021 survey from Ipsos, 9 in 10 Americans currently include meat as part of their diet. With that in mind, it won't be hard for most to spot the symptoms of a concerning health condition that's becoming more and more of a problem thanks to another rising trend. Researchers are warning that the increasing prevalence of one pest across the country could have serious con
Crispr Therapeutics said Thursday it will unveil the first data from human studies of its gene-edited lymphoma drug — and CRSP stock popped.
More than two years into the pandemic, there is plenty to celebrate but just as many ongoing concerns. In the last week alone, infections have increased by more than 21 percent and hospitalizations have gone up by over 16 percent, according to the Centers for Disease Control and Prevention (CDC). Just a month ago, the numbers were consistently and substantially dropping—and the about-face since then has been a stark reminder that the path forward is likely to be less linear than many of us had h
Fiber has a lot to offer—it can support your gut health, help you lose weight or and even keep you feeling full for longer. To help you reap the benefits of getting enough fiber each day, these breakfasts include at least 6 grams of fiber per serving. Plus, each recipe focuses on complex carbs, like whole grains, and sticks to heart-healthy levels of saturated fat and sodium for a meal that fits perfectly into a diabetes-friendly routine.
As mask mandates and vaccine requirements continue to disappear across the U.S., it may feel like the worst of the coronavirus pandemic is already behind us. In fact, many people appear hopeful for a COVID-free summer, as they plan upcoming vacations and holiday parties. Even some of the nation's top COVID advisers have shed some positive light on the country's progress. Anthony Fauci, MD, the White House's chief medical adviser and director of the National Institute of Allergy and Infectious Di
Dr. Anthony Fauci, the nation’s top infectious disease specialist, told The Root today that cases of the deadly Covid-19 virus are slowly rising again across the country and warned that Black Americans could be particularly at risk in the event a more aggressive variant should appear. Fauci spoke with The Root this afternoon where he clarified his own comments about where the nation stood on the status of the pandemic as the country nears the milestone of 1 million deaths from the virus, which o
(Reuters) -The U.S. Food & Drug Administration said on Friday it had approved Eli Lilly's injected drug tirzepatide, which has the brand name Mounjaro, to help improve blood sugar control in adults with type 2 diabetes. The FDA said Mounjaro, along with diet and exercise, improved blood sugar levels and was more effective than the other diabetes therapies with which it was compared in clinical studies. Mounjaro is designed to activate receptors for hormones involved in blood sugar control.
It’s expected that, after two years of multiple disruptions caused by the COVID-19 pandemic, there would be repercussions on our collective mental health. As recent research has shown, it is heavily impacting children and teens.
Singer died last month, one day before being admitted into the Country Music Hall of Fame
A French court has ordered Sanofi to pay more than 400,000 euros ($416,440) in damages to a family whose child suffered from a form of autism caused by its epilepsy drug Valproate, saying the drugmaker failed to inform about known side effects. The link, alongside physical malformation, had also been recognised in a landmark class action ruling in January, which could potentially lead to hundreds of millions of euros in compensation, though Sanofi said it would file an appeal. The latest ruling, made last week and seen by Reuters on Saturday, states that Sanofi must have known the risk that the drug, if taken by pregnant women, could cause malformations and "neuro-behavioural disorders" in children, which should have been mentioned in its attached leaflet.
Lung cancer patients could survive twice as long after a “pioneering” drug was approved on the NHS.
We're at another confusing point in the COVID-19 pandemic. Cases are rising, thanks to the highly contagious Omicron subvariants, at the same time that precautions are being relaxed nationwide and summer beckons. How should Americans conduct their lives now, and when is it necessary to protect against COVID-19? Dr. Anthony Fauci, the nation's top infectious-disease expert, recently appeared on CBS News to give an update on the status of the pandemic and deliver some important advice on when to w